Physician profile
Jesse Liu
NPI 1043348618
$9,564.73
in general payments reported to CMS, 2019-2025
33 companies · $2,604 in 2025
The $2,604 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $922 · 2020: $714 · 2021: $664 · 2022: $1,154 · 2023: $1,484 · 2024: $2,022 · 2025: $2,604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,027 · Education: $82.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,027.33 |
| Education | $82.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,598.05 | 2019-2025 | |
| Janssen Biotech, INC. | $1,231.73 | 2020-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $798.68 | 2019-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $756.17 | 2019-2025 | Xifaxan, Trulance, Uceris |
| Gilead Sciences, INC. | $594.36 | 2019-2025 | |
| Pfizer INC. | $556.23 | 2019-2025 | |
| Lilly USA, LLC | $405.80 | 2024-2025 | Omvoh |
| Medtronic, INC. | $298.84 | 2022-2024 | Endoflip, Linq II |
| Celltrion USA INC. | $296.41 | 2023-2025 | Vegzelma, Yuflyma, Zymfentra |
| Regeneron Healthcare Solutions, INC. | $249.62 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $214.55 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $197.50 | 2019-2024 | Dificid |
| Ucb, INC. | $142.42 | 2019 | |
| Genzyme Corporation | $131.66 | 2022-2023 | |
| Madrigal Pharmaceuticals | $127.25 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $109.18 | 2019-2024 | Ocaliva |
| Astellas Pharma US INC | $99.99 | 2019 | |
| Aimmune Therapeutics, INC. | $93.81 | 2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $83.20 | 2021-2024 | |
| Braintree Laboratories, INC. | $77.01 | 2020-2025 | Suflave, Sutab |
| Ardelyx, INC. | $72.67 | 2025 | Ibsrela |
| Novo Nordisk INC | $71.88 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $53.06 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $52.68 | 2023-2024 | Idacio |
| Abbott Laboratories | $46.52 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.78 | 2023-2024 | Cyltezo |
| Redhill Biopharma INC. | $35.30 | 2020-2023 | Talicia, Aemcolo |
| Nestle Healthcare Nutrition INC. | $24.74 | 2023 | |
| Ge Healthcare | $24.17 | 2025 | |
| Daiichi Sankyo INC. | $24.00 | 2019 | |
| W. L. Gore & Associates, INC. | $19.30 | 2020 | |
| Celgene Corporation | $16.59 | 2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $15.58 | 2025 | Iqirvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.